Newer anticonvulsants in the treatment of anxiety disorders
Abstract
This is the protocol for a review and there is no abstract. The objectives are as follows: 1) To use evidence from RCTs in providing an estimate of the overall effects of the newer anticonvulsants in improving treatment response and reducing symptom severity in the treatment of anxiety disorders. 2) To determine whether particular anticonvulsants are more effective and tolerable than others in the treatment of anxiety disorders. 3) To determine whether the particular anxiety disorder treated predicts the effectiveness of anticonvulsants in terms of efficacy and tolerability. 4) To identify which factors (clinical, methodological) predict response to pharmacotherapy. Copyright © 2006 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Description
Keywords
anticonvulsive agent, etiracetam, felbamate, gabapentin, lamotrigine, oxcarbazepine, placebo, pregabalin, tiagabine, topiramate, vigabatrin, zonisamide, anxiety disorder, aplastic anemia, clinical protocol, clinical trial, Cochrane Library, data extraction, data synthesis, disease severity, dizziness, drug effect, drug efficacy, drug tolerability, human, information processing, intervention study, liver toxicity, MEDLINE, meta analysis, methodology, Obsessive-compulsive disorder, outcome assessment, psychosis, publishing, randomization, rash, review, risk factor, sensitivity analysis, somnolence, Stevens Johnson syndrome, systematic review, toxic epidermal necrolysis, treatment outcome, treatment response, visual field defect
Citation
Cochrane Database of Systematic Reviews
4
4